Johnson & Johnson (JNJ) Current Deferred Tax Assets (2009 - 2015)
Johnson & Johnson's (JNJ) quarterly Current Deferred Tax Assets came in at $3.6 billion in Q3 2015, down 5.77% year-on-year from $3.8 billion in Q3 2014, and down 3.14% quarter-over-quarter from $3.7 billion in Q2 2015.
Johnson & Johnson (JNJ) Current Deferred Tax Assets (2009 - 2015) Analysis & Trends
Johnson & Johnson has disclosed Current Deferred Tax Assets across 7 years of filings, most recently posting $3.6 billion for Q3 2015.
- Current Deferred Tax Assets for Q3 2015 came in at $3.6 billion, down 5.77% year-over-year; the trailing twelve-month figure through Sep 2015 was $3.6 billion (down 5.77% YoY), and the FY2014 annual result was $3.6 billion, down 1.11% from the prior year.
- Current Deferred Tax Assets came in at $3.6 billion for Q3 2015 at Johnson & Johnson, down from $3.7 billion in the prior quarter.
- In the past five years, Current Deferred Tax Assets ranged from a high of $4.1 billion in Q2 2014 to a low of $2.2 billion in Q1 2011.
- The 5-year median for Current Deferred Tax Assets is $3.3 billion (2012), against an average of $3.2 billion.
- Across the five-year window, Current Deferred Tax Assets declined 20.37% in 2011 and soared 35.17% in 2012, its largest moves.
- Johnson & Johnson's Current Deferred Tax Assets stood at $2.5 billion in 2011, then advanced by 26.57% to $3.1 billion in 2012, then climbed by 14.91% to $3.6 billion in 2013, then decreased by 1.11% to $3.6 billion in 2014, then climbed by 1.09% to $3.6 billion in 2015.
- The last three Current Deferred Tax Assets figures came in at $3.6 billion (Q3 2015), $3.7 billion (Q2 2015), and $3.5 billion (Q1 2015), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 27, 2015 | 3.61 Bn |
| Sep 27, 2015 | 3.61 Bn |
| Jun 28, 2015 | 3.72 Bn |
| Jun 28, 2015 | 3.72 Bn |
| Mar 29, 2015 | 3.52 Bn |
| Mar 29, 2015 | 3.52 Bn |
| Dec 28, 2014 | 3.57 Bn |
| Dec 28, 2014 | 3.57 Bn |
| Sep 28, 2014 | 3.83 Bn |
| Sep 28, 2014 | 3.83 Bn |
| Jun 29, 2014 | 4.10 Bn |
| Jun 29, 2014 | 4.10 Bn |
| Mar 30, 2014 | 3.92 Bn |
| Mar 30, 2014 | 3.92 Bn |
| Dec 29, 2013 | 3.61 Bn |
| Dec 29, 2013 | 3.61 Bn |
| Sep 29, 2013 | 3.49 Bn |
| Sep 29, 2013 | 3.49 Bn |
| Jun 30, 2013 | 3.28 Bn |
| Jun 30, 2013 | 3.28 Bn |